


CLAIMS:

1. A compound of the formula I:

5



10

(I)

wherein:

ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may

15 contain 1-3 heteroatoms selected independently from O, N and S;

Z is -O-, -NH- or -S-;

n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2 or 3;

R² represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, C₁₋

20 alkoxy, C₁₋₃alkylsulphonyl, -NR³R⁴ (wherein R³ and R⁴, which may be the same or different, each represents hydrogen or C₁₋₃alkyl), or R⁵X¹- (wherein X¹ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR⁶C(O)-, -C(O)NR⁷-, -SO₂NR⁸-, -NR⁹SO₂- or -NR¹⁰- (wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and R⁵ is selected from one of the following twenty-two groups:

25 1) hydrogen, oxiranylC₁₋₄alkyl or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino; 2) C₁₋₅alkylX²C(O)R¹¹ (wherein X² represents -O- or -NR¹²- (in which R¹² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹¹ represents C₁₋₃alkyl, -NR¹³R¹⁴ or -OR¹⁵ (wherein R¹³, R¹⁴ and R¹⁵ which may be the same or different each represents hydrogen, C₁₋

30 alkyl or C₁₋₃alkoxyC₂₋₃alkyl));

3) C₁₋₅alkylX³R¹⁶ (wherein X³ represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NR¹⁷C(O)-, -C(O)NR¹⁸-, -SO₂NR¹⁹-, -NR²⁰SO₂- or -NR²¹- (wherein R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹⁶ represents

- hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋
- 5 C₄cynoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O)f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected
- 10 independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 4) C₁₋₅alkylX⁴C₁₋₅alkylX⁵R²² (wherein X⁴ and X⁵ which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR²³C(O)-, -C(O)NR²⁴-, -SO₂NR²⁵-, -NR²⁶SO₂- or -NR²⁷- (wherein R²³, R²⁴, R²⁵, R²⁶ and R²⁷ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋
- 15 3alkyl) and R²² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);
- 5) R²⁸ (wherein R²⁸ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cynoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O)f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected
- 20 independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 6) C₁₋₅alkylR²⁸ (wherein R²⁸ is as defined herein);
- 7) C₂₋₅alkenylR²⁸ (wherein R²⁸ is as defined herein);
- 8) C₂₋₅alkynylR²⁸ (wherein R²⁸ is as defined herein);
- 9) R²⁹ (wherein R²⁹ represents a pyridone group, a phenyl group or a 5-6-membered aromatic
- 30 heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from oxo, hydroxy, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -

- C(O)NR³⁰R³¹, -NR³²C(O)R³³ (wherein R³⁰, R³¹, R³² and R³³, which may be the same or different, each represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and a group -(O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which 5 cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 10) C₁₋₅alkylR²⁹ (wherein R²⁹ is as defined herein);
- 11) C₂₋₅alkenylR²⁹ (wherein R²⁹ is as defined herein);
- 12) C₂₋₅alkynylR²⁹ (wherein R²⁹ is as defined herein);
- 13) C₁₋₅alkylX⁶R²⁹ (wherein X⁶ represents -O-, -S-, -SO-, -SO₂-, -NR³⁴C(O)-, -C(O)NR³⁵-, -SO₂NR³⁶-, -NR³⁷SO₂- or -NR³⁸- (wherein R³⁴, R³⁵, R³⁶, R³⁷ and R³⁸ each independently 10 represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined herein);
- 14) C₂₋₅alkenylX⁷R²⁹ (wherein X⁷ represents -O-, -S-, -SO-, -SO₂-, -NR³⁹C(O)-, -C(O)NR⁴⁰-, -SO₂NR⁴¹-, -NR⁴²SO₂- or -NR⁴³- (wherein R³⁹, R⁴⁰, R⁴¹, R⁴² and R⁴³ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined herein);
- 15) 15) C₂₋₅alkynylX⁸R²⁹ (wherein X⁸ represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁴C(O)-, -C(O)NR⁴⁵-, -SO₂NR⁴⁶-, -NR⁴⁷SO₂- or -NR⁴⁸- (wherein R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷ and R⁴⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined herein);
- 16) C₁₋₄alkylX⁹C₁₋₄alkylR²⁹ (wherein X⁹ represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁹C(O)-, -C(O)NR⁵⁰-, -SO₂NR⁵¹-, -NR⁵²SO₂- or -NR⁵³- (wherein R⁴⁹, R⁵⁰, R⁵¹, R⁵² and R⁵³ each 20 independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined herein);
- 17) C₁₋₄alkylX⁹C₁₋₄alkylR²⁸ (wherein X⁹ and R²⁸ are as defined herein);
- 18) C₂₋₅alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, 25 aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
- 19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
- 20) C₂₋₅alkenylX⁹C₁₋₄alkylR²⁸ (wherein X⁹ and R²⁸ are as defined herein);
- 30) 21) C₂₋₅alkynylX⁹C₁₋₄alkylR²⁸ (wherein X⁹ and R²⁸ are as defined herein); and
- 22) C₁₋₄alkylR⁵⁴(C₁₋₄alkyl)_q(X⁹)_rR⁵⁵ (wherein X⁹ is as defined herein, q is 0 or 1, r is 0 or 1, and R⁵⁴ and R⁵⁵ are each independently selected from hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected 35

- independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄
- 5 C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl), with
- 10 the proviso that R⁵⁴ cannot be hydrogen);
- and additionally wherein any C₁₋₅alkyl, C₂₋₅alkenyl or C₂₋₅alkynyl group in R⁵X¹- which is linked to X¹ may bear one or more substituents selected from hydroxy, halogeno and amino); R¹ represents hydrogen, oxo, halogeno, hydroxy, C₁₋₄alkoxy, C₁₋₄alkyl, C₁₋₄alkoxymethyl, C₁₋₄alkanoyl, C₁₋₄haloalkyl, cyano, amino, C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₃alkanoyloxy, nitro, C₁₋₁₅alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, N-(C₁₋₄alkylsulphonyl)amino, N-(C₁₋₄alkylsulphonyl)-N-(C₁₋₄alkyl)amino, N,N-di(C₁₋₄alkylsulphonyl)amino, a C₃₋₇alkylene chain joined to two ring C carbon atoms, C₁₋₂₀alkanoylaminoC₁₋₄alkyl, carboxy or a group R⁵⁶X¹⁰ (wherein X¹⁰ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR⁵⁷C(O)-, -C(O)NR⁵⁸-, -SO₂NR⁵⁹-, -NR⁶⁰SO₂- or -NR⁶¹- (wherein R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰ and R⁶¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and R⁵⁶ is selected from one of the following twenty-two groups:
- 25 1) hydrogen, oxiranylC₁₋₄alkyl or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino; 2) C₁₋₅alkylX¹¹C(O)R⁶² (wherein X¹¹ represents -O- or -NR⁶³- (in which R⁶³ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁶² represents C₁₋₃alkyl, -NR⁶⁴R⁶⁵ or -OR⁶⁶ (wherein R⁶⁴, R⁶⁵ and R⁶⁶ which may be the same or different each represents hydrogen, C₁₋₃₀alkyl or C₁₋₃alkoxyC₂₋₃alkyl)); 3) C₁₋₅alkylX¹²R⁶⁷ (wherein X¹² represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NR⁶⁸C(O)-, -C(O)NR⁶⁹-, -SO₂NR⁷⁰-, -NR⁷¹SO₂- or -NR⁷²- (wherein R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹ and R⁷² each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁶⁷ represents

hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋

- 5 4cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected
- 10 independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 4) C₁₋₅alkylX¹³C₁₋₅alkylX¹⁴R⁷³ (wherein X¹³ and X¹⁴ which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR⁷⁴C(O)-, -C(O)NR⁷⁵-, -SO₂NR⁷⁶-, -NR⁷⁷SO₂- or -NR⁷⁸- (wherein R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷ and R⁷⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₄alkoxyC₂₋₃alkyl) and R⁷³ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);
- 5) R⁷⁹ (wherein R⁷⁹ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 20 6) C₁₋₅alkylR⁷⁹ (wherein R⁷⁹ is as defined herein);
- 7) C₂₋₅alkenylR⁷⁹ (wherein R⁷⁹ is as defined herein);
- 8) C₂₋₅alkynylR⁷⁹ (wherein R⁷⁹ is as defined herein);
- 9) R⁸⁰ (wherein R⁸⁰ represents a pyridone group, a phenyl group or a 5-6-membered aromatic
- 30 heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from oxo, hydroxy, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -

- C(O)NR⁸¹R⁸², -NR⁸³C(O)R⁸⁴ (wherein R⁸¹, R⁸², R⁸³ and R⁸⁴, which may be the same or different, each represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and a group -(-O)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which 5 cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 10) C₁₋₅alkylR⁸⁰ (wherein R⁸⁰ is as defined herein);
 - 11) C₂₋₅alkenylR⁸⁰ (wherein R⁸⁰ is as defined herein);
 - 12) C₂₋₅alkynylR⁸⁰ (wherein R⁸⁰ is as defined herein);
 - 13) C₁₋₅alkylX¹⁵R⁸⁰ (wherein X¹⁵ represents -O-, -S-, -SO-, -SO₂-, -NR⁸⁵C(O)-, -C(O)NR⁸⁶-, -10 SO₂NR⁸⁷-, -NR⁸⁸SO₂- or -NR⁸⁹- (wherein R⁸⁵, R⁸⁶, R⁸⁷, R⁸⁸ and R⁸⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined herein);
 - 14) C₂₋₅alkenylX¹⁶R⁸⁰ (wherein X¹⁶ represents -O-, -S-, -SO-, -SO₂-, -NR⁹⁰C(O)-, -C(O)NR⁹¹-, -SO₂NR⁹²-, -NR⁹³SO₂- or -NR⁹⁴- (wherein R⁹⁰, R⁹¹, R⁹², R⁹³ and R⁹⁴ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined herein);
 - 15) 15) C₂₋₅alkynylX¹⁷R⁸⁰ (wherein X¹⁷ represents -O-, -S-, -SO-, -SO₂-, -NR⁹⁵C(O)-, -C(O)NR⁹⁶-, -SO₂NR⁹⁷-, -NR⁹⁸SO₂- or -NR⁹⁹- (wherein R⁹⁵, R⁹⁶, R⁹⁷, R⁹⁸ and R⁹⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined herein);
 - 16) C₁₋₄alkylX¹⁸C₁₋₄alkylR⁸⁰ (wherein X¹⁸ represents -O-, -S-, -SO-, -SO₂-, -NR¹⁰⁰C(O)-, -C(O)NR¹⁰¹-, -SO₂NR¹⁰²-, -NR¹⁰³SO₂- or -NR¹⁰⁴- (wherein R¹⁰⁰, R¹⁰¹, R¹⁰², R¹⁰³ and R¹⁰⁴ each 20 independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined herein);
 - 17) C₁₋₄alkylX¹⁸C₁₋₄alkylR⁷⁹ (wherein X¹⁸ and R⁷⁹ are as defined herein);
 - 18) C₂₋₅alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino,
 - 25 aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
 - 19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
 - 20) C₂₋₅alkenylX¹⁸C₁₋₄alkylR⁷⁹ (wherein X¹⁸ and R⁷⁹ are as defined herein);
 - 30 21) C₂₋₅alkynylX¹⁸C₁₋₄alkylR⁷⁹ (wherein X¹⁸ and R⁷⁹ are as defined herein); and
 - 22) C₁₋₄alkylR¹⁰⁵(C₁₋₄alkyl)_x(X¹⁸)_yR¹⁰⁶ (wherein X¹⁸ is as defined herein, x is 0 or 1, y is 0 or 1, and R¹⁰⁵ and R¹⁰⁶ are each independently selected from hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected

- independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl) with the proviso that R¹⁰⁵ cannot be hydrogen);
- and additionally wherein any C₁₋₅alkyl, C₂₋₅alkenyl or C₂₋₅alkynyl group in R⁵⁶X¹⁰- which is linked to X¹⁰ may bear one or more substituents selected from hydroxy, halogeno and amino); with the proviso that one or more R¹ and/or one or more R² are selected from Q¹X¹- wherein X¹ is as defined herein and Q¹ is selected from one of the following groups:
- 15 1) C₁₋₄alkyl-Q¹³-C(O)-C₁₋₄alkyl-Q¹⁴ wherein Q¹³ is C₁₋₃alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or may bear 1, 2 or 3 substituents selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, C₁₋₆alkanoylC₁₋₆alkyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl), and Q¹⁴ is a 5-6-membered saturated or partially unsaturated heterocyclic group containing at least one nitrogen atom and optionally containing a further nitrogen atom wherein Q¹⁴ is linked to C₁₋₆alkanoyl through a nitrogen

- atom and wherein Q¹⁴ optionally bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears 1, 2 or 3 substituents selected from C₂₋₅alkenyl, C₂₋₅salkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, C₁₋₆alkanoylC₁₋₆alkyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy,
- 10 di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl);
- 2) Q² (wherein Q² is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C₁₋₆alkanoylC₁₋₆alkyl and optionally bears a further 1 or 2 substituents selected from C₂₋₅alkenyl, C₂₋₅salkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, C₁₋₆alkanoylC₁₋₆alkyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 30 3) C₁₋₅alkylW¹Q² (wherein W¹ represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NQ³C(O)-, -C(O)NQ⁴-, -SO₂NQ⁵-, -NQ⁶SO₂- or -NQ⁷- (wherein Q³, Q⁴, Q⁵, Q⁶ and Q⁷ each independently represents hydrogen, C₁₋₃alkyl, C₁₋₃alkoxyC₂₋₃alkyl, C₂₋₅alkenyl, C₂₋₅salkynyl or C₁₋₄haloalkyl) and Q² is as defined herein);

- 4) $C_{1-5}\text{alkyl}Q^2$ (wherein Q^2 is as defined herein);
- 5) $C_{2-5}\text{alkenyl}Q^2$ (wherein Q^2 is as defined herein);
- 6) $C_{2-5}\text{salkynyl}Q^2$ (wherein Q^2 is as defined herein);
- 7) $C_{1-4}\text{alkyl}W^2C_{1-4}\text{alkyl}Q^2$ (wherein W^2 represents $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{NQ}^8\text{C(O)}-$, C(O)NQ^9- , $-\text{SO}_2\text{NQ}^{10}-$, $-\text{NQ}^{11}\text{SO}_2-$ or $-\text{NQ}^{12}-$ (wherein Q^8 , Q^9 , Q^{10} , Q^{11} and Q^{12} each independently represents hydrogen, $C_{1-3}\text{alkyl}$, $C_{1-3}\text{alkoxy}C_{2-3}\text{alkyl}$, $C_{2-5}\text{alkenyl}$, $C_{2-5}\text{salkynyl}$ or $C_{1-4}\text{haloalkyl}$) and Q^2 is as defined herein);
- 8) $C_{2-5}\text{alkenyl}W^2C_{1-4}\text{alkyl}Q^2$ (wherein W^2 and Q^2 are as defined herein);
- 9) $C_{2-5}\text{salkynyl}W^2C_{1-4}\text{alkyl}Q^2$ (wherein W^2 and Q^2 are as defined herein);
- 10) $C_{1-4}\text{alkyl}Q^{15}(C_{1-4}\text{alkyl})_j(W^2)_kQ^{16}$ (wherein W^2 is as defined herein, j is 0 or 1, k is 0 or 1, and Q^{15} and Q^{16} are each independently selected from hydrogen, $C_{1-3}\text{alkyl}$, cyclopentyl, cyclohexyl and a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which $C_{1-3}\text{alkyl}$ group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-4}\text{alkoxy}$ and which cyclic group may bear either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or may bear 1, 2 or 3 substituents selected from $C_{2-5}\text{alkenyl}$, $C_{2-5}\text{salkynyl}$, $C_{1-6}\text{fluoroalkyl}$, $C_{1-6}\text{alkanoyl}$, $C_{1-6}\text{alkanoyl}C_{1-6}\text{alkyl}$, $\text{amino}C_{1-6}\text{alkanoyl}$, $C_{1-4}\text{alkylamino}C_{1-6}\text{alkanoyl}$, $\text{di}(C_{1-4}\text{alkyl})\text{amino}C_{1-6}\text{alkanoyl}$, $C_{1-6}\text{fluoroalkanoyl}$, carbamoyl, $C_{1-4}\text{alkylcarbamoyl}$, $\text{di}(C_{1-4}\text{alkyl})\text{carbamoyl}$, carbamoyl $C_{1-6}\text{alkyl}$, $C_{1-4}\text{alkylcarbamoyl}C_{1-6}\text{alkyl}$, $\text{di}(C_{1-4}\text{alkyl})\text{carbamoyl}C_{1-6}\text{alkyl}$, $C_{1-6}\text{alkylsulphonyl}$, $C_{1-6}\text{fluoroalkylsulphonyl}$, oxo, hydroxy, halogeno, cyano, $C_{1-4}\text{cyanoalkyl}$, $C_{1-4}\text{alkyl}$, $C_{1-4}\text{hydroxyalkyl}$, $C_{1-4}\text{alkoxy}$, $C_{1-4}\text{alkoxy}C_{1-4}\text{alkyl}$, $C_{1-4}\text{alkylsulphonyl}C_{1-4}\text{alkyl}$, $C_{1-4}\text{alkoxycarbonyl}$, $C_{1-4}\text{aminoalkyl}$, $C_{1-4}\text{alkylamino}$, $\text{di}(C_{1-4}\text{alkyl})\text{amino}$, $C_{1-4}\text{alkylamino}C_{1-4}\text{alkyl}$, $\text{di}(C_{1-4}\text{alkyl})\text{amino}C_{1-4}\text{alkyl}$, $C_{1-4}\text{alkylamino}C_{1-4}\text{alkoxy}$, $\text{di}(C_{1-4}\text{alkyl})\text{amino}C_{1-4}\text{alkoxy}$ and a group $-(-\text{O}-)_f(C_{1-4}\text{alkyl})_g\text{ringD}$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from $C_{1-4}\text{alkyl}$), with the provisos that Q^{15} cannot be hydrogen and one or both of Q^{15} and Q^{16} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from $C_{1-6}\text{alkanoyl}C_{1-6}\text{alkyl}$ and optionally bears 1 or 2 further substituents selected from those defined herein);

- 11) $C_{1-4}alkylQ^{15}C_{1-4}alkanoylQ^{16n}$ wherein Q^{15} is as defined herein and is not hydrogen and Q^{16n} is a 5-6-membered saturated or partially unsaturated heterocyclic group containing at least one nitrogen atom and optionally containing a further nitrogen atom wherein Q^{16n} is linked to $C_{1-6}alkanoyl$ through a nitrogen atom and wherein Q^{16n} bears either one substituent
5 selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears 1, 2 or 3 substituents selected from $C_{2-5}alkenyl$, $C_{2-5}alkynyl$, $C_{1-6}fluoroalkyl$, $C_{1-6}alkanoyl$, $C_{1-6}alkanoylC_{1-6}alkyl$, amino $C_{1-6}alkanoyl$, $C_{1-4}alkylaminoC_{1-6}alkanoyl$, di($C_{1-4}alkyl$)amino $C_{1-6}alkanoyl$, $C_{1-6}fluoroalkanoyl$, carbamoyl, $C_{1-4}alkylcarbamoyl$, di($C_{1-4}alkyl$)carbamoyl, carbamoyl $C_{1-6}alkyl$, $C_{1-4}alkylcarbamoylC_{1-6}alkyl$, di($C_{1-4}alkyl$)carbamoyl $C_{1-6}alkyl$, $C_{1-6}alkylsulphonyl$, $C_{1-6}fluoroalkylsulphonyl$, oxo, hydroxy, halogeno, cyano, $C_{1-4}cyanoalkyl$, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$, $C_{1-4}alkylsulphonylC_{1-4}alkyl$, $C_{1-4}alkoxycarbonyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, di($C_{1-4}alkyl$)amino, $C_{1-4}alkylaminoC_{1-4}alkyl$, di($C_{1-4}alkyl$)amino $C_{1-4}alkyl$, $C_{1-4}alkylaminoC_{1-4}alkoxy$, di($C_{1-4}alkyl$)amino $C_{1-4}alkoxy$ and a group $-(O-O)_f(C_{1-4}alkyl)_g$ ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-
15 membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from $C_{1-4}alkyl$); with the proviso that one or both of Q^{15} and Q^{16n} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy
20 to form a bicyclic ring, or bears at least one substituent selected from $C_{1-6}alkanoylC_{1-6}alkyl$ and optionally bears 1 or 2 further substituents selected from those defined herein; and additionally wherein any $C_{1-5}alkyl$, $C_{2-5}alkenyl$ or $C_{2-5}alkynyl$ group in Q^1X^1- which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino); or a salt thereof.

25


2. A compound according to claim 1 wherein ring C is a 9-10-membered heteroaromatic bicyclic moiety which contains 1 or 2 nitrogen atoms..

3. A compound according to claim 1 or claim 2 wherein Z is -O- or -S-.

30

4. A compound according to any one of claims 1-3 wherein R¹ represents methyl or fluoro.

5. A compound according to claim 1 of the formula IIb:



(IIb)

wherein:

M is -CH- or -N-;

15 nc is 0, 1 or 2;

R<sup>2c</sup> is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl;

R<sup>2d</sup> is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro;

20 R<sup>2a</sup> and R<sup>2b</sup> are each independently selected from hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkylsulphonyl, -NR<sup>3a</sup>R<sup>4a</sup> (wherein R<sup>3a</sup> and R<sup>4a</sup>, which may be the same or different, each represents hydrogen or C<sub>1-3</sub>alkyl), and Q<sup>1</sup>X<sup>1</sup> wherein Q<sup>1</sup> and X<sup>1</sup> are as defined in claim 1;

Q<sup>1</sup> and X<sup>1</sup> are as defined in claim 1;


Z<sup>a</sup> is -O- or -S-;

25 with the proviso that at least one of R<sup>2a</sup> and R<sup>2b</sup> is Q<sup>1</sup>X<sup>1</sup> wherein Q<sup>1</sup> and X<sup>1</sup> are as defined in claim 1;


or a salt thereof.

6. A compound according to claim 5 wherein one of R<sup>2a</sup> and R<sup>2b</sup> is methoxy and the other 30 is Q<sup>1</sup>X<sup>1</sup> wherein X<sup>1</sup> is -O- and Q<sup>1</sup> is selected from one of the following groups:

1) C<sub>1-4</sub>alkyl-Q<sup>13</sup>-C(O)-C<sub>1-4</sub>alkyl-Q<sup>14</sup> wherein Q<sup>13</sup> and Q<sup>14</sup> are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,




and




wherein Q¹⁴ is linked to C₁₋₆alkanoyl through a nitrogen atom;

2) Q² (wherein Q² is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,



and



5

which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C₂₋₄alkanoylC₁₋₃alkyl and optionally bears a further 1 or 2 substituents selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, C₂₋₄alkanoylC₁₋₃alkyl, aminoC₁₋₆alkanoyl, C₁₋


10 alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋

15 alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O-)(C₁₋₄alkyl)_fringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));


20 3) C₁₋₅alkylQ² (wherein Q² is as defined herein);

4) C₁₋₄alkylW²C₁₋₄alkylQ² (wherein W² is as defined in claim 1 and Q² is as defined herein);

5) C₁₋₄alkylQ¹⁵(C₁₋₄alkyl)_j(W²)_kQ¹⁶ (wherein W² is as defined in claim 1, j is 0 or 1, k is 0 or 1, and Q¹⁵ and Q¹⁶ are each independently selected from a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,




and




25

which heterocyclic group may bear either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or may bear 1, 2 or 3 substituents selected from C₂₋

- salkenyl, C₂₋₅salkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, C₂₋₄alkanoylC₁₋₃alkyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy,
- 5 halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with
- 10 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl), with the proviso one or both of Q¹⁵ and Q¹⁶ must be a 5-6-membered heterocyclic group as defined herein which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C₂₋₄alkanoylC₁₋₃alkyl and optionally bears 1 or
- 15 2 further substituents selected from those defined herein);
- 6) C₁₋₄alkylQ¹⁵C₁₋₄alkanoylQ¹⁶ⁿ wherein Q¹⁵ is as defined herein and Q¹⁶ⁿ is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,



and




- wherein Q¹⁶ⁿ is linked to C₁₋₆alkanoyl through a nitrogen atom and wherein Q¹⁶ⁿ bears either
- 20 one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears 1, 2 or 3 substituents selected from C₂₋₅salkenyl, C₂₋₅salkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, C₂₋₄alkanoylC₁₋₃alkyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with
- 25 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear
- 30 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear

one or more substituents selected from C₁₋₄alkyl); with the proviso that one or both of Q¹⁵ and Q¹⁶ⁿ must be a 5-6-membered heterocyclic group as defined herein which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C₂₋₄alkanoylC₁₋₃alkyl and optionally bears


- 5 1 or 2 further substituents selected from those defined herein;
and additionally wherein any C₁₋₅alkyl, C₂₋₅alkenyl or C₂₋₅alkynyl group in Q¹X¹- which is linked to X¹ may bear one or more substituents selected from hydroxy, halogeno and amino).

7. A compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other
10 is Q¹X¹ wherein X¹ is -O- and Q¹ is

C₁₋₄alkyl-Q¹³-C(O)-C₁₋₄alkyl-Q¹⁴ wherein Q¹³ and Q¹⁴ are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,



and




wherein Q¹⁴ is linked to C₁₋₆alkanoyl through a nitrogen atom.


15

8. A compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q¹X¹ wherein X¹ is -O- and Q¹ is selected from one of the following groups:

1) Q² (wherein Q² is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,



and



20

which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears one substituent selected from C₂₋₄alkanoylC₁₋₃alkyl; and

2) C₁₋₅alkylQ² (wherein Q² is as defined herein).

25

9. A compound according to claim 7 or claim 8 wherein R^{2a} is methoxy.

10. A compound according to claim 1 selected from:

- 7-{{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[3-methyl-1*H*-indol-5-yl)oxy]quinazoline,
- 7-{{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[2-methyl-1*H*-indol-6-yl)oxy]quinazoline,
- 5 7-{{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[2-methyl-1*H*-indol-5-yl)oxy]quinazoline,
- 6-methoxy-4-[3-methyl-1*H*-indol-5-yl)oxy]-7-{{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy} quinazoline,
- 6-methoxy-4-[2-methyl-1*H*-indol-6-yl)oxy]-7-{{[1-(pyrrolidin-1-ylacetyl)piperidin-4-
- 10 10]methoxy} quinazoline,
- 6-methoxy-4-[2-methyl-1*H*-indol-5-yl)oxy]-7-{{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy} quinazoline,
- 6-methoxy-4-[2-methyl-1*H*-indol-5-yl)oxy]-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
- 15 6-methoxy-4-[3-methyl-1*H*-indol-5-yl)oxy]-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
- 4-[(2,3-dimethyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
- 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,
- 20 7-{{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[2,3-dimethyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
- 7-{{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[3-methyl-1*H*-indol-5-yl)oxy]quinazoline,
- 25 7-{{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[2-methyl-1*H*-indol-5-yl)oxy]quinazoline,
- 7-{{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
- 6-methoxy-4-[2-methyl-1*H*-indol-5-yl)oxy]-7-{{2-[4-(pyrrolidin-1-ylacetyl)piperazin-1-
- 30 30]ethoxy} quinazoline,
- 7-{{[1-(acetylmethyl)piperidin-4-yl]oxy}-6-methoxy-4-[2-methyl-1*H*-indol-6-yl)oxy]quinazoline,

7-{{[1-(acetyl methyl)piperidin-4-yl]oxy}-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline,

7-{{[1-(acetyl methyl)piperidin-4-yl]oxy}-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline,

5 or a salt thereof.

11. A compound according to claim 1 selected from:

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrol-5-yl)ethoxy]quinazoline,

10 7-{{2-[4-(acetyl methyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline,

7-{{2-[4-(acetyl methyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline,

or a salt thereof.


15

12. A compound according to any one of the preceding claims in the form of a pharmaceutically acceptable salt.

13. A process for the preparation of a compound according to claim 1 of the formula I or
20 salt thereof which comprises:


(a) the reaction of a compound of the formula III:

25



(III)

30 (wherein R² and m are as defined in claim 1 and L¹ is a displaceable moiety), with a compound of the formula IV:




(IV)

(wherein ring C, R¹, Z and n are as defined in claim 1) optionally followed by the addition of a
5 substituent on a heterocyclic ring of R¹ or R²;

(b) for compounds of formula I and salts thereof wherein at least one R² is R⁵X¹ or
Q¹X¹ wherein R⁵ and Q¹ are as defined in claim 1, and X¹ is -O-, -S-, -OC(O)- or -NR¹⁰-
(wherein R¹⁰ independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) the reaction
of a compound of the formula V:

10



15

(V)

(wherein ring C, Z, R¹, R² and n are as defined in claim 1 and X¹ is as defined in this section
and s is an integer from 0 to 2) with one of the compounds of the formulae VIa-b:




20

(wherein R⁵ and Q¹ are as defined in claim 1 and L¹ is as defined herein);

(c) for compounds of the formula I and salts thereof wherein at least one R² is R⁵X¹ or
Q¹X¹ wherein R⁵ and Q¹ are as defined in claim 1, and X¹ is -O-, -S-, -OC(O)- or -NR¹⁰-
(wherein R¹⁰ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) the reaction of a

25 compound of the formula VII:



5

(VII)

with one of the compounds of the formulae VIIIa-b:

$$R^5-X^1-H \quad (VIIIa)$$

10 Q¹-X¹-H (VIIIb)

$$Q^1-X^1-H \quad (VIIIb)$$

(wherein R^1 , R^2 , R^5 , Q^1 , ring C, Z and n are as defined in claim 1, L^1 and s are as defined herein and X^1 is as defined in this section;

(d) for compounds of the formula I and salts thereof wherein at least one R² is R⁵X¹ or Q¹X¹ wherein X¹ is as defined in claim 1, R⁵ is C₁₋₅alkylR¹¹³, wherein R¹¹³ is selected from 15 one of the following nine groups:

1) $X^{19}C_{1-3}$ alkyl (wherein X^{19} represents -O-, -S-, $-SO_2^-$, $-NR^{114}C(O)-$ or $-NR^{115}SO_2^-$ (wherein R^{114} and R^{115} which may be the same or different are each hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl);

2) $\text{NR}^{116}\text{R}^{117}$ (wherein R^{116} and R^{117} which may be the same or different are each hydrogen,
20 $\text{C}_{1-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxyC}_{2-3}\text{alkyl}$);

3) $X^{20}C_{1-3}\text{alkyl}X^5R^{22}$ (wherein X^{20} represents $-O-$, $-S-$, $-\text{SO}_2-$, $-\text{NR}^{118}\text{C(O)-}$, $-\text{NR}^{119}\text{SO}_2-$ or $-\text{NR}^{120}-$ (wherein R^{118} , R^{119} , and R^{120} which may be the same or different are each hydrogen, $C_{1-3}\text{alkyl}$ or $C_{1-3}\text{alkoxyC}_{2-3}\text{alkyl}$) and X^5 and R^{22} are as defined in claim 1);

4) R²⁸ (wherein R²⁸ is as defined in claim 1);
 25 5) X²¹R²⁹ (wherein X²¹ represents -O-, -S-, -SO₂-, -NR¹²¹C(O)-, -NR¹²²SO₂-, or -NR¹²³-
 (wherein R¹²¹, R¹²², and R¹²³ which may be the same or different are each hydrogen, C₁₋₃alkyl
 or C₁₋₂alkoxyC₂₋₃alkyl) and R²⁹ is as defined in claim 1);

6) $X^{22}C_{1-3}alkylR^{29}$ (wherein X^{22} represents -O-, -S-, - SO_2 -, - $NR^{124}C(O)-$, - $NR^{125}SO_2-$ or - $NR^{126}-$ (wherein R^{124} , R^{125} and R^{126} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxy$).

30 $\text{alkoxyC}_2\text{-alkyl}$) and R^{29} is as defined in claim 1);

7) R²⁹ (wherein R²⁹ is as defined in claim 1);

8) $X^{22}C_{1-4}alkylR^{28}$ (wherein X^{22} and R^{28} are as defined in claim 1); and


9) $R^{54}(C_{1-4}\text{alkyl})_q(X^9)_rR^{55}$ (wherein q, r, X⁹, R⁵⁴ and R⁵⁵ are as defined in claim 1);

Q^1 is $C_{1-5}\text{alkyl}Q^{27}$ wherein Q^{27} is selected from one of the following six groups:

- 1) $Q^{13}-C(O)-C_{1-4}\text{alkyl}Q^{14}$ (wherein Q^{13} and Q^{14} are as defined in claim 1);
- 2) W^1Q^2 (wherein W^1 and Q^2 are as defined in claim 1);
- 3) Q^2 (wherein Q^2 is as defined in claim 1);
- 4) $W^2C_{1-4}\text{alkyl}Q^2$ (wherein W^2 and Q^2 are as defined in claim 1);
- 5) $Q^{15}(C_{1-4}\text{alkyl})_j(W^2)_kQ^{16}$ (wherein W^2 , j , k , Q^{15} and Q^{16} are as defined in claim 1);
- 6) $Q^{15}C_{1-4}\text{alkanoyl}Q^{16n}$ (wherein Q^{15} and Q^{16n} are as defined in claim 1);

the reaction of a compound of the formula IX:

10



15

(IX)

(wherein X^1 , R^1 , R^2 , ring C, Z and n are as defined in claim 1 and L^1 and s are as defined herein) with one of the compounds of the formulae Xa-b:



20



(wherein R^{113} and Q^{27} are as defined herein) optionally followed by the addition of a substituent on a heterocyclic ring of R^1 or R^2 ;

and when a salt of a compound of formula I is required, reaction of the compound obtained with an acid or base whereby to obtain the desired salt.

25

14. A pharmaceutical composition which comprises a compound of the formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

30 15. Use of a compound of the formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal.

16. A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.